Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. announced that its product, methylphenidate hydrochloride sustained-release capsules, has been included in the National Medical Insurance Directory for 2025, which will positively impact the company's market promotion and sales [1] Group 1: Product Information - The product included is methylphenidate hydrochloride sustained-release capsules, classified under code XN06B, used for treating Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 and above [1] - The inclusion in the National Medical Insurance Directory means that the product will be reimbursed under Category B during the agreement period [1] Group 2: Market Impact - The inclusion of the product in the National Medical Insurance Directory is expected to enhance market promotion and sales, leading to a positive impact on the company's operating performance [1] - The new National Medical Insurance Directory will officially take effect on January 1, 2026, and is not expected to have a significant impact on the company's performance for the current fiscal year [1]

Core Viewpoint - The announcement highlights that Xuanzhu Biotechnology, a subsidiary of Four环医药, has successfully included its innovative drug Pirlosilib Tablets (brand name: XuanYueNing®) in the 2025 National Basic Medical Insurance Directory, which will be implemented on January 1, 2026 [1] Group 1 - The inclusion of XuanYueNing® in the National Basic Medical Insurance Directory will enhance its affordability and accessibility for patients [1] - This development is expected to promote the market penetration and increase sales scale of the drug, positively impacting the long-term operational growth of Xuanzhu Biotechnology [1] - Xuanzhu Biotechnology plans to actively cooperate in the implementation of the insurance policy, focusing on hospital access and expanding coverage in core and broader markets to improve patient access to medication [1]

Core Viewpoint - China Resources Sanjiu Pharmaceutical Co., Ltd. has successfully included its product Yiqi Qingfei Granules in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025 version) through negotiations, which is expected to enhance the company's product portfolio in the respiratory field and strengthen its market leadership position [1] Group 1 - Yiqi Qingfei Granules received the drug registration certificate from the National Medical Products Administration in January 2025 and is currently undergoing post-market academic promotion and online sales [1] - The 2025 version of the National Medical Insurance Catalog will officially take effect on January 1, 2026, marking the first inclusion of Yiqi Qingfei Granules in this catalog [1] - The short-term impact on the company's operating performance is not expected to be significant, but the inclusion is seen as a positive step for the company's strategic positioning in the respiratory product sector [1]

Core Viewpoint - China Resources Sanjiu (000999.SZ) announced that its drug Yiqi Qingfei Granules has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025 through negotiations [1] Group 1 - The inclusion of Yiqi Qingfei Granules marks a significant milestone for the company, enhancing its market access and potential revenue streams [1] - This decision is part of a broader initiative by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security to update the drug catalog [1]

华润三九（000999）(000999.SZ)公告，据国家医保局、人力资源社会保障部关于印发《国家基本医疗 保险、生育保险和工伤保险药品目录》以及《商业健康保险创新药品目录》的通知，公司药品益气清肺 颗粒通过谈判首次纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》。 ...

四环医药(00460)发布公告，本集团旗下非全资附属公司轩竹生物科技股份有限公司(轩竹生物)自主研发 的创新药吡洛西利片(商品名：轩悦宁)首次纳入《国家基本医疗保险、生育保险和工伤保险药品目录 (2025年)》(2025国家基本医保目录)。2025国家基本医保目录将于2026年1月1日正式执行。 本次医保谈判结果有助于轩竹生物进一步提高轩悦宁在患者中的可负担性和可及性，有利于进一步推动 该药物的市场推广、提升销售规模，对轩竹生物的长期经营发展具有积极影响。轩竹生物将积极配合推 进医保政策落地，持续推进医院准入工作、拓展核心市场及广阔市场的覆盖，以期不断提升患者的用药 可及性。 ...

Core Viewpoint - The company, Hai Chen Pharmaceutical, successfully renewed the contract for its injectable Labetalol Hydrochloride (50mg) and has also included the 150mg version in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1] Group 1 - The injectable Labetalol Hydrochloride (50mg) has successfully renewed its contract [1] - The injectable Labetalol Hydrochloride (150mg) has been included for the first time in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1]

Core Viewpoint - The inclusion of the drug Praluent® (Pralsetinib capsules, 100 mg) in China's National Medical Insurance Catalog is a significant development for the company, as it will officially take effect on January 1, 2026, enhancing the drug's market access and potential sales in the region [1]. Group 1: Drug Approval and Indications - Praluent® is an oral targeted therapy approved by the National Medical Products Administration (NMPA) for treating adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are RET gene fusion positive, as well as for adult and pediatric patients aged 12 and above with advanced or metastatic RET mutation medullary thyroid carcinoma (MTC) requiring systemic treatment [1][2]. - The drug has also been approved in Hong Kong for treating adult patients with metastatic RET fusion-positive NSCLC and in Taiwan for similar indications, including advanced or metastatic RET fusion-positive thyroid cancer [1]. Group 2: Commercialization and Partnerships - The drug Praluent® was developed by Blueprint Medicines, which was acquired by Sanofi in July 2025, indicating a strategic partnership that may enhance the drug's development and commercialization efforts [2]. - The company has granted exclusive commercialization rights for Praluent® in mainland China to Shanghai Elios Pharmaceutical Technology Co., Ltd. as of November 2023, which may streamline marketing and distribution efforts in the region [2].

本次医保谈判结果有助于本公司进一步提高轩悦宁在患者中的可负担性和可及性，有利于进一步推动该 药物的市场推广、提升销售规模，对本公司的长期经营发展具有积极影响。本公司将积极配合推进医保 政策落地，持续推进医院准入工作、拓展核心市场及扩大市场的覆盖，以期不断提升患者的用药可及 性。 轩竹生物-B(02575)发布公告，本公司自主研发的创新药吡洛西利片(商品名：轩悦宁)首次纳入《国家基 本医疗保险、生育保险和工伤保险药品目录(2025年)》(2025国家基本医保目录)。2025国家基本医保目 录将于2026年1月1日正式执行。 ...

智通财经APP讯，轩竹生物-B(02575)发布公告，本公司自主研发的创新药吡洛西利片(商品名：轩悦宁) 首次纳入《国家基本医疗保险、生育保险和工伤保险药品目录( 2025年 )》(2025国家基本医保目录)。 2025国家基本医保目录将于2026年1月1日正式执行。 本次医保谈判结果有助于本公司进一步提高轩悦宁在患者中的可负担性和可及性，有利于进一步推动该 药物的市场推广、提升销售规模，对本公司的长期经营发展具有积极影响。本公司将积极配合推进医保 政策落地，持续推进医院准入工作、拓展核心市场及扩大市场的覆盖，以期不断提升患者的用药可及 性。 ...